CA2515347A1 - Screening for modulators of fat storage - Google Patents

Screening for modulators of fat storage Download PDF

Info

Publication number
CA2515347A1
CA2515347A1 CA002515347A CA2515347A CA2515347A1 CA 2515347 A1 CA2515347 A1 CA 2515347A1 CA 002515347 A CA002515347 A CA 002515347A CA 2515347 A CA2515347 A CA 2515347A CA 2515347 A1 CA2515347 A1 CA 2515347A1
Authority
CA
Canada
Prior art keywords
rip
target protein
rip140
reporter gene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002515347A
Other languages
English (en)
French (fr)
Inventor
Malcolm George Parker
Roger White
Goran Leonardsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Limited
Malcolm George Parker
Roger White
Goran Leonardsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Limited, Malcolm George Parker, Roger White, Goran Leonardsson filed Critical Imperial College Innovations Limited
Publication of CA2515347A1 publication Critical patent/CA2515347A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
CA002515347A 2003-02-03 2004-02-03 Screening for modulators of fat storage Abandoned CA2515347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302446.0 2003-02-03
GBGB0302446.0A GB0302446D0 (en) 2003-02-03 2003-02-03 Screening for modulators of fat storage
PCT/GB2004/000413 WO2004070347A2 (en) 2003-02-03 2004-02-03 Screening for modulators of fat storage

Publications (1)

Publication Number Publication Date
CA2515347A1 true CA2515347A1 (en) 2004-08-19

Family

ID=9952335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002515347A Abandoned CA2515347A1 (en) 2003-02-03 2004-02-03 Screening for modulators of fat storage

Country Status (6)

Country Link
EP (1) EP1590674A2 (ja)
JP (1) JP2006518591A (ja)
AU (1) AU2004209335A1 (ja)
CA (1) CA2515347A1 (ja)
GB (1) GB0302446D0 (ja)
WO (1) WO2004070347A2 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691823B2 (en) * 2004-03-05 2010-04-06 University Of Massachusetts RIP140 regulation of glucose transport
JP2006090948A (ja) * 2004-09-27 2006-04-06 Fuji Photo Film Co Ltd バイオセンサーを用いたスクリーニング方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
JP4296608B2 (ja) * 1997-08-27 2009-07-15 田辺三菱製薬株式会社 Ｐｐａｒのアゴニスト及びアンタゴニストのスクリーニング方法
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
AU1758401A (en) * 1999-11-12 2001-06-06 Merck & Co., Inc. Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
US20020004205A1 (en) * 2000-03-30 2002-01-10 Consler Thomas G. Method of investigating functional molecular interactions and reagents for use therein
US20030104975A1 (en) * 2001-06-14 2003-06-05 Johan Auwerx Cofactor-based screening method for nuclear receptor modulators and related modulators

Also Published As

Publication number Publication date
EP1590674A2 (en) 2005-11-02
WO2004070347A2 (en) 2004-08-19
WO2004070347A3 (en) 2004-12-16
GB0302446D0 (en) 2003-03-05
AU2004209335A1 (en) 2004-08-19
JP2006518591A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
Liu et al. Mitophagy receptor FUNDC1 is regulated by PGC‐1α/NRF1 to fine tune mitochondrial homeostasis
Greenblatt et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice
Koh et al. Lipin1 is a key factor for the maturation and maintenance of adipocytes in the regulatory network with CCAAT/enhancer-binding protein α and peroxisome proliferator-activated receptor γ2
Luiro et al. Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments
Ludbrook et al. Excess DAX1 leads to XY ovotesticular disorder of sex development (DSD) in mice by inhibiting steroidogenic factor-1 (SF1) activation of the testis enhancer of SRY-box-9 (Sox9)
de Souza et al. The estrogen receptor α colocalizes with proopiomelanocortin in hypothalamic neurons and binds to a conserved motif present in the neuron-specific enhancer nPE2
Heikkilä et al. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production
Stayrook et al. Regulation of carbohydrate metabolism by the farnesoid X receptor
Chang et al. NT-PGC-1α protein is sufficient to link β3-adrenergic receptor activation to transcriptional and physiological components of adaptive thermogenesis
Subkhangulova et al. SORCS 1 and SORCS 3 control energy balance and orexigenic peptide production
Kubota et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd
US20110218229A1 (en) SIRT1 Modulation of Adipogenesis and Adipose Function
Akashi et al. A positive role for PERIOD in mammalian circadian gene expression
López-Rodríguez et al. Persistent vs transient alteration of folliculogenesis and estrous cycle after neonatal vs adult exposure to bisphenol A
Ito et al. Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification
Oyabu et al. FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting
CA2588646A1 (en) Methods to identify ligands of hormone nuclear receptors
Fleming et al. Developmental expression of steroidogenic factor 1 in a turtle with temperature-dependent sex determination
WO2003027634A2 (en) Identification of modulatory molecules using inducible promoters
Clark et al. Selective estrogen receptor-beta (SERM-beta) compounds modulate raphe nuclei tryptophan hydroxylase-1 (TPH-1) mRNA expression and cause antidepressant-like effects in the forced swim test
Qamar et al. Anti-steroidogenic factor ARR19 inhibits testicular steroidogenesis through the suppression of Nur77 transactivation
Lau et al. Dexras1 interacts with FE65 to regulate FE65-amyloid precursor protein-dependent transcription
Debril et al. Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity
Arena et al. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways
Al-Massadi et al. Pharmacological and genetic manipulation of p53 in brown fat at adult but not embryonic stages regulates thermogenesis and body weight in male mice

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead